Tandem Diabetes Care Shares Drop 12% After Private Placement for Senior Notes
By Chris Wack
Tandem Diabetes Care shares were down 12%, to $27.43, after the diabetes-technology company said it intends to offer $250 million of its convertible senior notes due 2029 in a private placement.
The stock closed Monday's session 13% higher, but is down 34% in the past 12 months.
Tandem said it intends to grant the initial purchasers of the notes an option to purchase up to an additional $37.5 million principal amount of notes.
The company expects to use the proceeds from the offering, together with cash on hand, to repurchase some 1.50% convertible senior notes due 2025 and to repurchase up to $30 million of its shares in privately negotiated transactions.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 05, 2024 12:44 ET (17:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
10 Top-Performing Dividend Stocks
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters
-
CVS Earnings: Weak Medicare Advantage Profits Cut Into 2024 Outlook
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth